PARAGOULD, Ark. — Arkansas Methodist Medical Center (AMMC) proudly announces the introduction of LEQEMBI (Lecanemab), a groundbreaking FDA-approved medication aimed at slowing the progression of Alzheimer’s disease and enhancing the quality of life for patients and their caregivers.
LEQEMBI represents a significant advancement in Alzheimer’s treatment, as it targets the detrimental amyloid beta protein associated with the formation of plaques in the brains of individuals with the disease. Unlike previous treatments, LEQEMBI not only alleviates symptoms but also slows the progression of the disease itself by selectively binding to and clearing amyloid plaques from the brain.
Dr. Ron South, a Neurologist at AMMC Neurology Associates, emphasized the importance of early detection and preventative measures alongside the introduction of LEQEMBI. “LEQEMBI is a significant step forward in Alzheimer’s treatment, but it shouldn’t detract from the importance of early detection and preventative measures,” said Dr. South. “Our comprehensive evaluation process helps us determine eligibility for LEQEMBI treatment, ensuring we can provide this innovative therapy to those who will benefit most.”
AMMC stands out as one of the select institutions in Arkansas offering a comprehensive LEQEMBI program, positioning itself as a leader in advanced Alzheimer’s care within the region. This program underscores AMMC’s commitment to enhancing patient care and providing hope and support to those affected by Alzheimer’s.
LEQEMBI is administered through patient-friendly outpatient infusion services at AMMC, known for their accessibility and convenience. Dr. South emphasized their commitment to patient comfort and care, highlighting stress-free parking and straightforward access to services.
Dr. South expressed pride in offering LEQEMBI as part of AMMC’s commitment to delivering exceptional care and innovative treatments. “Our goal is to improve the lives of those affected by Alzheimer’s disease and offer hope for a brighter future,” he said.
AMMC’s LEQEMBI program includes a dedicated Dementia Coordinator, Jessica Nutt, APRN, who plays a pivotal role in providing continuity of care for all patients. “Jessica works closely with patients, families, and our team to ensure seamless communication and support throughout the treatment process,” noted Dr. South. “It’s about more than just medicine; it’s about comprehensive care for the individual.”
Current patients of AMMC Neurology Associates are encouraged to discuss LEQEMBI with their provider during their next scheduled appointment. Those not currently under the care of AMMC Neurology Associates but seeking evaluation for Alzheimer’s disease are asked to request a referral from their current provider to AMMC Neurology Associates. For more information on LEQEMBI and how to request a referral, visit the Neurology services page at www.myammc.org.
Arkansas Methodist Medical Center in Paragould is recognized as a leader in providing progressive, compassionate healthcare to residents throughout Northeast Arkansas and Southeast Missouri. Additional information about AMMC is available at www.myammc.org.
SHARE THIS STORY WITH OTHERS:
Discover more from NEA Report
Subscribe to get the latest posts sent to your email.
Be the first to comment